Breast Cancer

Patients with chemotherapy-naïve, HER2-low hormone receptor-positive metastatic breast cancer experienced antitumor activity via combination therapy with Arimidex or Faslodex plus Enhertu, according to data from the phase 1b DESTINY-Breast08 trial.

Oct. 8, 2019 was the last day of chemotherapy for my girl.

My first oncologist was the nicest man. I only gave him up because we moved to a different state.

“I have found many survivors to be very strong women who seem like they have things under control but it’s always important for family and friends to check in,” television personality, author and breast cancer survivor Giuliana Rancic told CURE.

Now having conquered three cancers and am fighting metastatic pancreatic cancer, scars from all the surgeries within the last 26 years have shown victories and hope.

Results from a study found that child-related factors and depression in mothers with breast cancer were not related to cancer.

Data showed that metabolic and genetic factors could contribute to aggressive tumors in Latin American and non-Hispanic White patients with breast cancer.

A breast cancer survivor explains “one of the beautiful things” about antibody drug conjugates in the metastatic breast cancer space.

Could killing cancer be as simple as changing your diet?

CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.

Presurgical Keytruda Plus Chemo, Postsurgical Keytruda Continued to Show Benefits in in patients with high-risk, early-stage triple-negative breast cancer.

Opdivo and non–anthracycline containing chemotherapy before surgery produced promising pathologic complete response rates regardless of whether Opdivo was administered before or during treatment with carboplatin and paclitaxel in patients with stage 1 to 2B triple-negative breast cancer.

Preliminary study results examining the bispecific antibody, CDK4/6 inhibitor and hormone therapy combination in patients with advanced breast cancer were presented at SABCS.

Results from the ADAPTcycle trial found that endocrine therapy plus ovarian suppression can generate high response rates in patients with HR-positive, early breast cancer, regardless of age.

A recent phase 3 APTneo Michelangelo trial added Tecentriq to neoadjuvant Herceptin plus Perjeta and chemotherapy which did not lead to a statistically significant improvement in pathologic complete response in patients with HER2-positive operable breast cancer.

Kadcyla outperformed Herceptin regarding overall- and invasive disease-free survival in patients with HER2-positive early breast cancer that still had remaining invasive disease after undergoing neoadjuvant therapy.

Patients with ER-positive, HER2-negative, ESR1-mutant advanced breast cancer experienced improvements in progression-free survival when being treated with Orserdu, study results showed.

Having had cancer twice before, I know the choreography if I have it again.

Findings were presented at the 2023 San Antonio Breast Cancer Symposium from a study investigating real-world patients who received Enhertu for advanced breast cancer.

A triple-negative breast cancer survivor discussed disparities she faced when undergoing cancer care.

Dato-DXd (datopotamab deruxtecan) as a form of treatment compared to chemotherapy resulted in improved progression-free survival for patients with previously treated hormone receptor-positive/HER2-negative inoperable or metastatic breast cancer.

The introduction of Tukysa to Kadcyla emtansine significantly improved progression-free survival versus placebo plus Kadcyla in patients with previously treated HER2-positive metastatic breast cancer.

This year, as winter approaches, I’ve been thinking about how I winterize my life and my exercise so that I am ready for more when spring arrives.

Race demonstrated differences in overall survival outcomes, but not for three-year recurrence-free survival in patients with HR-positive, HER2-negative breast cancer, according to data.

The combination of Keytruda to neoadjuvant chemotherapy, followed by Keytruda in combination with endocrine therapy improved pathologic response rates for patients with early-stage, high-risk, estrogen receptor (ER)–positive/HER2-negative breast cancer.